ABAbCellera Biologics Inc. ABCL · NASDAQ
$11.80 -6.94% (-$0.88)
- Market cap
- $3.87B
- Enterprise value
- $3.89B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 58.5x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -15.0%
- Gross margin
- 75.0%
- Net margin
- -248.8%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 1.19
- Free float
- 64.5%
About the company
AbCellera Biologics Inc. (ABCL) is a biotechnology company specializing in the development of monoclonal antibodies and other biological therapeutics for the treatment of various diseases, including infectious diseases and cancer. The company utilizes advanced technologies such as artificial intelligence and wide-scale antibody scanning to identify and develop potentially effective therapies. AbCellera collaborates with pharmaceutical companies on drug development and therapeutic approaches. With its innovations in the field of biological therapeutics and partnerships with the pharmaceutical industry, investing in AbCellera Biologics Inc. (ABCL) shares may present an interesting investment opportunity for investors interested in the biotechnology and medical sectors.
Sector
Healthcare
Industry
Biotechnology
CEO
Carl Hansen
Employees
562
Headquarters
Vancouver
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number